Log In
Print
BCIQ
Print
Print this Print this
 

bococizumab (PF-04950615, PF-4950615, RN316)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionHuman mAb against proprotein convertase subtilisin/kexin type 9 (PCSK9)
Molecular Target Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today